Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Int J Neurosci. 2016 Nov;126(11):1002-6. doi: 10.3109/00207454.2015.1092443. Epub 2015 Oct 6.

PMID:
26365467
2.

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3627-33. doi: 10.1007/s00405-014-3398-3. Epub 2014 Nov 25.

PMID:
25421643
3.

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U.

Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23.

PMID:
24456504
4.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

5.

A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.

Grauslund M, Thougaard AV, Füchtbauer A, Hofland KF, Hjorth PH, Jensen PB, Sehested M, Füchtbauer EM, Jensen LH.

Mol Pharmacol. 2007 Oct;72(4):1003-14. Epub 2007 Jul 10.

6.

Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.

Rømer MU, Kirkebjerg Due A, Knud Larsen J, Hofland KF, Christensen IJ, Buhl-Jensen P, Almholt K, Lerberg Nielsen O, Brünner N, Lademann U.

Thromb Haemost. 2005 Oct;94(4):859-66.

PMID:
16270643
7.

Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.

Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, Jensen PB.

Clin Cancer Res. 2005 Sep 15;11(18):6722-9.

8.

Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Hofland KF, Thougaard AV, Sehested M, Jensen PB.

Clin Cancer Res. 2005 May 15;11(10):3915-24.

9.

Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.

Lademann U, Rømer MU, Jensen PB, Hofland KF, Larsen L, Christensen IJ, Brünner N.

Eur J Cancer. 2005 May;41(7):1095-100.

PMID:
15862760
10.

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.

Schroeder PE, Hofland KF, Jensen PB, Sehested M, Langer SW, Hasinoff BB.

Cancer Chemother Pharmacol. 2004 Jan;53(1):91-3. Epub 2003 Oct 22.

PMID:
14574459
11.

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.

Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB.

Cancer Chemother Pharmacol. 2003 Aug;52(2):167-74. Epub 2003 May 15.

PMID:
12750840

Supplemental Content

Loading ...
Support Center